Coronado Industries' Medical Director Treats Patients in China With 100% Success Rate for Lowering IOP.

Business Editors and Health/Medical Writers

FOUNTAIN HILLS, Ariz.--(BW HealthWire)--Jan. 3, 2000

Coronado Industries Inc. (OTC BB: CDIK) (www.coronadoindustries.com) Monday announced that its medical director, Leo D. Bores, M.D., treated 29 glaucoma patients on a recent trip to Xian, China.

All of the patients treated experienced a lowering of intraocular pressure (IOP) as a result of treatment with Coronado's patented technology, pneumatic trabeculoplasty(TM) (PNT(TM)). Follow up with the patients since the treatment indicates that the IOP has remained lower as a result of the treatment.

Bores hosted a seminar on the PNT(TM) technology at a medical symposium in Xian Dec. 11, 1999. Everblooming Enterprises, a major distributor of ophthalmic devices in China, sponsored the trip. The Chinese Medical Association's Glaucoma team and top ophthalmologists from Beijing, Shanghai, and several other major provinces attended the seminar. Chinese National Television also broadcast a story on his visit and the technology. "This is an important step toward introducing Coronado's PNT(TM) device into the healthcare community and major hospitals of China," said Gary Smith, president of Coronado Industries. "The latest statistics show that 7 to 9 million people in China suffer from glaucoma and approximately 25 percent or 2 million are children."

Bores also demonstrated the PNT(TM) technology for top Chinese military officials and was allowed unprecedented access at military bases in China. Based on the success of this first trip, Bores has been invited back to China in February. He is expected to visit major hospitals in Hong Kong and Singapore and conduct symposiums on glaucoma and the PNT(TM) technology for groups of physicians and other influential government officials. Bores' return trip will kick off Everblooming Enterprises' marketing campaign as a distributor of the PNT(TM) products in China. "This can prove to be a valuable revenue stream for our company," said G. Richard Smith, CEO of Coronado industries.

Approximately 66.8 million people worldwide suffer from primary glaucoma according to a Johns Hopkins University School of Medicine study. Glaucoma is a progressive disease and is the second leading cause of blindness. More than 7.5 million Americans suffer from Glaucoma.

Glaucoma occurs when the optic nerve is damaged by high intraocular pressure (IOP). The optic nerve is responsible for sending impulses to the brain, which translates those signals into sight. When the nerve is damaged, the signals cease to be transmitted and loss of vision occurs. Currently, patients rely on eye drops or surgery to lower IOP. Coronado Industries' PNT(TM) technology is a non-invasive medical procedure that lessens, if not eliminates patients' dependence on drops without the risk and cost of surgery.

Applicable to open-angle and pigmentary glaucoma, the two most common types of glaucoma, PNT(TM) uses a suction device that is applied to the eye for 1 to 2 minutes. The treatment is proven safe and effective with no known side effects and is less costly than traditional therapies. Often one treatment is sufficient, but there is no risk in subsequent treatments if needed, as frequently as every three months. Evaluation of approximately four years of data from an ongoing study of patients receiving PNT(TM) has shown the procedure, originally designed to treat Primary Open Angle Glaucoma (POAG), pigmentary glaucoma and glaucoma associated with pseudoexfoliation of the lens capsule, is of value in treating ocular hypertension, as well.

Safe Harbor Statement

The statements contained in this release which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.

Coronado Industries, through its two wholly owned subsidiaries American Glaucoma and Ophthalmic International, manufactures devices to treat forms of glaucoma and offers glaucoma diagnosis and treatment under an I.D.E Study (Investigational Device Exemption). Pending FDA approval, Coronado will license its patented treatment procedure and equipment in the United States. Coronado's Pneumatic Trabeculoplasty (PNT(TM)) procedure uses a non-invasive, patented, low-cost pneumatic device that has proven to be an effective and safe treatment option for glaucoma. In December 1998, Coronado was granted a CE Mark from the European Commission, which serves as a "passport" to allow a manufacturer to freely sell its products within the European Marketplace.